Advertisement

Drugs & Aging

, Volume 11, Issue 4, pp 285–295 | Cite as

Current and Emerging Treatments for Pancreatic Cancer

  • William F. Regine
  • William J. John
  • Mohammed Mohiuddin
Disease Management

Summary

The worldwide annual pancreatic cancer death rate equals its estimated annual incidence. Surgery has been considered the only curative modality for this disease, but only 5 to 15% of patients are candidates for potentially curative resection. Evidence that postoperative adjuvant treatment improves outcome has been limited to a single randomised trial of a well tolerated split-course chemoradiation regimen. More intensive regimens have since been developed and are associated with, at best, a modest improvement in patient outcome.

The potentially significant morbidity associated with pancreaticoduodenectomy, which can compromise the delivery of postoperative adjuvant chemoradiation, has led to the development of preoperative adjuvant (‘neoadjuv-ant’) chemoradiation in these patients. Although experience suggests that such an approach is feasible, its ultimate impact awaits further evaluation.

Combined modality therapy has produced the most promising results in patients with unresectable or locally advanced disease. However, only modest improvements in median survival and minimal increases in long term survival have so far been achieved. This observation has encouraged many investigators to devise innovative methods of delivering therapy, including radioisotope implantation and intraoperative radiation therapy (IORT). Combined modality therapy with radioisotope implantation appears to have the greatest potential for improving local control and survival in these patients. IORT may be associated with lower morbidity than radioisotope implantation, but its impact may be limited by the radiobiological disadvantage associated with single dose boost therapy.

Although new radiosensitising drugs are being tested, the problem of distant metastasis remains significant. New chemotherapeutic agents such as gemcitabine appear to have the potential to produce better results than those achieved over the last 35 years with fluorouracil. Investigations into the optimal integration of different therapeutic modalities, along with continued advances in surgery, radiation and systemic therapy, should lead to the increased use of modern multi-modality interventions. In turn, this will lead us towards further improvements in outcomes for patients with pancreatic carcinoma.

Keywords

Pancreatic Cancer Gemcitabine Octreotide Pancreatic Carcinoma Preoperative Chemoradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer JClin 1997; 47: 5–27CrossRefGoogle Scholar
  2. 2.
    Parkin D, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594–606PubMedCrossRefGoogle Scholar
  3. 3.
    Douglass H. Adjuvant therapy for pancreatic cancer. World J Surg 1995; 19: 170–4CrossRefGoogle Scholar
  4. 4.
    Shibamoto Y, Manabe T, Baba M, et al. High dose, external beam and intraoperative radiotherapy in the treatment of re-sectable pancreatic cancer. Int J Radiat Oncol Biol Phys 1990; 19: 605–11PubMedCrossRefGoogle Scholar
  5. 5.
    American Cancer Society. Cancer facts and figures: 1991. Atlanta: American Cancer Society, 1991Google Scholar
  6. 6.
    Connolly M, Dawson P, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206: 366–73PubMedCrossRefGoogle Scholar
  7. 7.
    Singh S, Longmire W, Reber H. Surgical palliation for pancreatic cancer: the UCLA experience. Ann Surg 1990; 212: 132–9PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenberg JM, Welch JP, Macaulay WP Cancer of the head of the pancreas: an institutional review with emphasis on surgical therapy. J Surg Oncol 1985; 28: 217–21PubMedCrossRefGoogle Scholar
  9. 9.
    Tsuchiya R, Noda T, Harada M, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77–81PubMedCrossRefGoogle Scholar
  10. 10.
    Funovics JM, Karner J, Pratschner T, et al. Current trends in the management of carcinoma of the pancreatic head. Hepatogastroenterology 1989; 36: 450–5PubMedGoogle Scholar
  11. 11.
    Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving?. Ann Surg 1995; 221(1): 59–66PubMedCrossRefGoogle Scholar
  12. 12.
    Piorkowski RJ, Believernicht SW, Lawrence Jr W, et al. Pancreatic and periampullary carcinoma: experience with 200 patients over a 12-year period. Am J Surg 1982; 143: 189–93PubMedCrossRefGoogle Scholar
  13. 13.
    Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987; 60: 2284–303PubMedCrossRefGoogle Scholar
  14. 14.
    Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68–73PubMedCrossRefGoogle Scholar
  15. 15.
    Trede M, Chir B, Schwall G, et al. Survival after pancreatoduodenectomy. Ann Surg 1990; 21(4): 447–58CrossRefGoogle Scholar
  16. 16.
    Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenec-tomy for cancer of the head of the pancreas: two hundred and one patients. Ann Surg 1995; 221(6): 721–33PubMedCrossRefGoogle Scholar
  17. 17.
    Gastrointestinal Tumor Study Group. Therapy of locally un-resected pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads) + 5-fluorouracil, and high dose radiation + 5-fluorouracil. Cancer 1981; 48: 1705–10CrossRefGoogle Scholar
  18. 18.
    Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991; 21: 1137–43PubMedCrossRefGoogle Scholar
  19. 19.
    Tepper J, Nardi G, Suit H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973 - analysis of surgical failure and implications for radiation therapy. Cancer 1976; 37: 1519–24PubMedCrossRefGoogle Scholar
  20. 20.
    Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 12: 899–903CrossRefGoogle Scholar
  21. 21.
    Douglass HO, Strablein DM. Ten year follow-up of first generation surgical adjuvant studies of the Gastrointestinal Tumor Study Group. In: Salmon SE, editor. Adjuvant therapy of cancer IV. Philadelphia: WB. Saunders, 1990: 405–15Google Scholar
  22. 22.
    Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006–10CrossRefGoogle Scholar
  23. 23.
    Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation + 5-fluorouracil. Int J Radiat Oncol Biol Phys 1993; 26: 483–9PubMedCrossRefGoogle Scholar
  24. 24.
    Yeo CJ, Hruban RH, Kern SE, et al. Adenocarcinoma of the pancreas: factors influencing outcome after pancreaticoduo-denectomy M the Johns Hopkins experience. Cancer Bull 1994; 46(6): 504–10Google Scholar
  25. 25.
    Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15(3): 928–37PubMedGoogle Scholar
  26. 26.
    Mohiuddin M, Rosato F, Schuricht A, et al. Carcinoma of the pancreas - the Jefferson experience 1975-1988. Eur J Surg Oncol 1994; 20: 13–20PubMedGoogle Scholar
  27. 27.
    O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331(8): 502–7PubMedCrossRefGoogle Scholar
  28. 28.
    Whittington R, Neuberg D, Tester WJ, et al. Protracted intravenous fluorouracil infusion with radiation therapy management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Group trial. J Clin Oncol 1995; 13(1): 227–32PubMedGoogle Scholar
  29. 29.
    Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980; 46: 1945–9PubMedCrossRefGoogle Scholar
  30. 30.
    Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre- or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9: 911–5PubMedCrossRefGoogle Scholar
  31. 31.
    Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradia-tion and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335–9PubMedCrossRefGoogle Scholar
  32. 32.
    Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int Radiat J Oncol Biol Phys 1994; 30(1): 161–7CrossRefGoogle Scholar
  33. 33.
    Hoffman JP, Weese JL, Lipsitz S, et al. Preoperative chemoradiation for patients with resectable pancreatic adenocarcinoma: an Eastern Cooperative Group (ECOG) phase II study [abstract]. Proc Am Soc Clin Oncol 1995; 14: 201Google Scholar
  34. 34.
    Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167: 104–13PubMedCrossRefGoogle Scholar
  35. 35.
    Nagakawa T, Konishi I, Ueno K, et al. The results and problems of extensive surgery for carcinoma of the head of the pancreas. Jpn J Surg 1991; 21: 262–7PubMedCrossRefGoogle Scholar
  36. 36.
    Todd KE, Gloor B, Lane JS, et al. Resection of locally advanced pancreatic cancer after downstaging with continuous infusion 5-FU, mitomycin-C, leucovorin (LV) and persantine. Gastro-enterology 1997; 112 Suppl. 4: A1479Google Scholar
  37. 37.
    Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy: does it have a role in the palliation of pancreatic cancer?. Ann Surg 1996; 223(6): 718–28PubMedCrossRefGoogle Scholar
  38. 38.
    Moertel CG. Chemotherapy of gastrointestinal cancer. N Engl J Med 1978; 299: 1049–52PubMedCrossRefGoogle Scholar
  39. 39.
    Smith FP, Schein PS. Chemotherapy of pancreatic cancer. Semin Oncol 1979; 6(3): 368–77PubMedGoogle Scholar
  40. 40.
    Cullinan SA, Moertel CG, Fleming TR, et al., and the North Central Cancer Treatment Group. A comparison of three che-motherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 253: 2061–7PubMedCrossRefGoogle Scholar
  41. 41.
    Gunderson LL, Martin JK, Kvols LK, et al. Intraoperative and external beam irradiation ∓ 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1987; 13: 319–29PubMedCrossRefGoogle Scholar
  42. 42.
    Dobelbower RR, Borgelt BB, Strubler KA, et al. Precision radiotherapy for cancer of the pancreas: technique and results. Int J Radiat Oncol Biol Phys 1980; 6: 1127–34PubMedCrossRefGoogle Scholar
  43. 43.
    Flickinger JC, Jawalekar K, Deutsch M, et al. Split course radiation therapy for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1988; 15: 359–64PubMedCrossRefGoogle Scholar
  44. 44.
    Haslam JB, Cavanaugh PJ, Stroup SL. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 1973; 32: 1341–5PubMedCrossRefGoogle Scholar
  45. 45.
    Gastrointestinal Tumor Study Group. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 1979; 5: 1643–7CrossRefGoogle Scholar
  46. 46.
    Gastrointestinal Tumor Study Group. Treatment of locally un-resectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751–5CrossRefGoogle Scholar
  47. 47.
    Moertel CG, Childs Jr DS, Reitemeir RJ, et al. Combined 5-flu-orouracil and supervoltage radiation therapy of locally un-resectable gastrointestinal cancer. Lancet 1969; II: 865–7CrossRefGoogle Scholar
  48. 48.
    Whittington R, Dobelbower RR, Mohiuddin M, et al. Radiotherapy of unresectable pancreatic carcinoma: a six year experience with 104 patients. Int J Radiat Oncol Biol Phys 1981; 7: 1639–44PubMedCrossRefGoogle Scholar
  49. 49.
    Shipley WU, Nardi GL, Cohen AM, et al. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma of the pancreas with 1-125 implantation. Cancer 1980; 45: 709–14PubMedCrossRefGoogle Scholar
  50. 50.
    Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with 1-125 implantation. Int J Radiat Oncol Biol Phys 1989; 17: 931–5PubMedCrossRefGoogle Scholar
  51. 51.
    Mohiuddin M, Cantor RJ, Biermann W, et al. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1988; 148: 79–84CrossRefGoogle Scholar
  52. 52.
    Mohiuddin M, Rosato F, Barbot D, et al. Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1992; 23: 305–11PubMedCrossRefGoogle Scholar
  53. 53.
    Mohiuddin M, Regine WF, Rosato F, et al. A comparison of intraoperative radiation therapy (IORT) and I-125 implantation for cancer of the pancreas. In: Schildberg FW, Willich N, Kramling H-J, editors. Proceedings of the 4th International Symposium on Intraoperative Radiation Therapy: Munich: 1992. Essen: 315-23Google Scholar
  54. 54.
    Kaul R, Cohen L, Hendrickson F, et al. Pancreatic carcinoma: results with fast neutron therapy. Int J Radiat Oncol Biol Phys 1981; 7: 173–8PubMedCrossRefGoogle Scholar
  55. 55.
    Cohen L, Woodruff KH, Hendrickson FR, et al. Response of pancreatic cancer to local irradiation with high-energy neutrons. Cancer 1985; 56: 1235–41PubMedCrossRefGoogle Scholar
  56. 56.
    Castro JR, Saunders WM, Quivey JM, et al. Clinical problems in radiotherapy of carcinoma of the pancreas. Am J Clin Oncol 1982; 5: 579–87PubMedCrossRefGoogle Scholar
  57. 57.
    Levin PL, Connely RR, DeVesa SS. Demographic characteristics of cancer of the pancreas: mortality, incidence, and survival. Cancer 1981; 47: 1456–68PubMedCrossRefGoogle Scholar
  58. 58.
    Shapiro TM. Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs. Whipple resection in good risk patients. Ann Surg 1975; 182: 715–21PubMedCrossRefGoogle Scholar
  59. 59.
    Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984; 200: 289–96PubMedCrossRefGoogle Scholar
  60. 60.
    Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988; 61: 1110–6PubMedCrossRefGoogle Scholar
  61. 61.
    Tepper JE, Noyes D, Krall JM, et al. Intraoperative radiation therapy of pancreatic carcinoma: a report of RTOG-8505. Int J Radiat Oncol Biol Phys 1991; 21: 1145–9PubMedCrossRefGoogle Scholar
  62. 62.
    Hall EJ, Brenner DJ. Radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 1993; 25: 381–5PubMedCrossRefGoogle Scholar
  63. 63.
    Safran H, King TP, Choy H, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol 1997; 15(3): 901–7PubMedGoogle Scholar
  64. 64.
    Burris HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6): 2403–13PubMedGoogle Scholar
  65. 65.
    Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347–53PubMedCrossRefGoogle Scholar
  66. 66.
    Miller KM, Picus J, Lochner P, et al. A phase II trial of LY231514 in patients with unresectable pancreas cancer. Proc Am Soc Clin Oncol 1997; 16: 297Google Scholar
  67. 67.
    Wong A, Chan A. Survival benefit of tamoxifen therapy in ad-enocarcinoma of pancreas: a case-control study. Cancer 1993; 71: 2200–3PubMedCrossRefGoogle Scholar
  68. 68.
    Rosenberg L, Barkun AN, Denis MH, et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 23–8PubMedCrossRefGoogle Scholar
  69. 69.
    Burch PA, Block M, Wieand HS, et al. A phase III evaluation of octreotide (somatostatin) versus chemotherapy with 5-FU or 5-FU leucovorin in advance exocrine pancreatic cancer: a NCCTG study [abstract 488]. Proc Am Soc Clin Oncol 1995; 14: 203Google Scholar
  70. 70.
    Buchler M, Sulkowski U, Pederzoli P, et al. A phase II study of octreotide (SMS) in advanced pancreatic cancer [abstract 642]. Proc Am Soc Clin Oncol 1994; 14: 215Google Scholar
  71. 71.
    Cascinu S, Del Ferro E, Catalano G. A randomized trial of octreotide versus best supportive care in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995; 71: 97–101PubMedCrossRefGoogle Scholar
  72. 72.
    Weckbecker G, Stolz B, Raulf F, et al. Cyclooctapeptide analogs of somatostatin for the treatment and scintigraphic localization of tumors. Proc Am Assoc Cancer Res 1994; 35: 381Google Scholar
  73. 73.
    Hoshi T, Imai M, Ogawa K. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol 1994; 55: 84–91PubMedCrossRefGoogle Scholar
  74. 74.
    Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568–73PubMedGoogle Scholar
  75. 75.
    Mohiuddin M, Ahmed MM, Venkatasubbarao K. C-Ki-ras mutations in peripheral blood of pancreatic cancer patients: a marker for early tumor metastasis. Int J Radiat Oncol Biol Phys 1996; 34(1): 161–6PubMedCrossRefGoogle Scholar
  76. 76.
    Aoki K, Yoshida T, Sugimura T, et al. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810–6PubMedGoogle Scholar
  77. 77.
    Mohiuddin M, Regine WF, Stevens J, et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995; 13(11): 2764–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • William F. Regine
    • 1
  • William J. John
    • 2
  • Mohammed Mohiuddin
    • 1
  1. 1.Chandler Medical Center, Department of Radiation MedicineUniversity of KentuckyLexingtonUSA
  2. 2.Markey Cancer Center, Division of Hematology/OncologyUniversity of KentuckyLexingtonUSA

Personalised recommendations